政府对Pharmac药房设定2026年新要求：继续提升药品可及性与效率
新西兰副卫生部长大卫·西摩（David Seymour）今日宣布，对国家药品采购机构Pharmac提出更明确的2026/27年度工作期望，要求其在固定预算内继续提高效率，为新西兰人提供更多所需药物与医疗技术。
西摩表示：
“对于许多新西兰人来说，药品资助关乎生死，或决定是否能摆脱长期痛苦。这也是本届政府重点关注的领域。”
他强调，Pharmac必须在既定预算范围内进一步提升效率，让资金“发挥更大作用”。
2026/27年度核心要求
政府对Pharmac提出以下主要目标：
- 确保药品评估、采购及特殊情况申请流程更顺畅，更有利于患者获取药物
- 加强在决策中对健康、社会及财政影响的综合考量
- 持续纳入患者、护理人员及家庭的意见
- 提升药品资助决策的时效性与透明度，包括：
- 设定评估时间目标
- 增加公开报告
- 更快发布决策记录
- 加强与患者团体、供应商及相关机构合作
- 投资数据与数字基础设施，包括引入人工智能（AI）
政府对Pharmac改革方向的评价
西摩表示，Pharmac已经从一个“仅管理固定预算的机构”，转变为一个更加开放、强调协作并主动争取改善资金与机制的机构。
他指出，这一变化得益于此前“指导信（Letters of Expectations）”带来的改革压力。
已取得的进展
政府总结Pharmac在以下方面已取得进展：
1. 机构文化改革
- 完成12个月“重置计划”（Reset Programme）
- 通过内外部咨询制定新的愿景与战略方向
- 启动旧有药品清单系统（Pharmaceutical Schedule）数字化升级
2. 加强合作与采购机制
- 加快药品评估流程（试点项目）
- 成立医疗器械供应商咨询小组
- 举办消费者参与研讨会
- 强化消费者参与团队
- 扩大年度招标的公众参与
3. 提升药品可及性
- 与国际专家合作，学习药品社会影响评估最佳实践
- 与Health NZ建立医疗器械采购合作机制
- 改善药品与医疗设备获取渠道
资金投入大幅增加
西摩表示，政府已为Pharmac提供历史最高预算支持。
截至目前，总资金规模达：
- 4年总预算：72亿纽元
其中包括：
- 2026预算新增：5,400万纽元（4年期）
- 2024年6月追加：6.04亿纽元（4年期）
- 2024预算基础投资：17.7亿纽元（用于弥补此前短期资金缺口）
患者受益情况
政府表示，资金增加已带来明显成效：
- 已做出135项药品资助或扩大适用范围决定
- 其中包括47种癌症药物
- 预计首年将惠及超过68万名患者
政府立场
西摩总结表示：
“到目前为止的进展令人鼓舞，但仍有更多工作要做。倾听患者与公众的声音，将继续是Pharmac未来改革的核心。”
他强调，Pharmac将进入长期改革的下一阶段，以持续提升药品可及性与医疗公平性。
Associate Health Minister David Seymour has today announced more clear expectations for Pharmac to continue delivering the medicines and medical technology that Kiwis need, more efficiently.
“For many New Zealanders, funding for pharmaceuticals is life or death, or the difference between a life of pain and suffering or living freely. That’s why it has been a focus of this Government,” Mr Seymour says.
“My expectation is that Pharmac continues to deliver for Kiwis within its fixed budget. Pharmac will need to find efficiencies to make their budget go further, because that’s what Kiwi patients and their families deserve.”
The expectations for Pharmac for 2026/27 include:
Ensuring assessment, procurement and exceptional circumstances processes continue to work for patients and support access to medicines.
Strengthening how Pharmac considers the wider health, social and fiscal impacts of funding decisions.
Continuing to reflect the voices of patients, carers and families in decision-making.
Further improving the timeliness and transparency of medicine funding decisions, including introducing assessment timeframes targets, public reporting, and faster publication of decision records.
Building on engagement with consumer groups, suppliers and other stakeholders to improve collaboration and planning to achieve the best results for Kiwi patients.
Investing in data and digital infrastructure to enhance core functions, including the use of AI.
“Pharmac has gone for focussing solely on managing their fixed budget to an agency that seeks collaboration and advocates for further funding. I want to acknowledge Pharmac for the work they have done to respond to my previous Letters of Expectations,” Mr Seymour says.
Pharmac achievements from previous letters of expectations:
Changed their culture, by:
Delivering a 12-month Reset Programme with input from the Consumer and Patient Working Group.
Developing a new vision and strategic priorities following significant external and internal consultation.
Investing in data and digital infrastructure, including beginning work to redevelop the aging Pharmaceutical Schedule.
Built productive consumer and procurement partnerships by:
Speeding up its processes, including completing a streamlined assessment pilot.
Strengthening partnerships with key stakeholders, including establishing a new Medical Devices Supplier Reference Group.
Taking part in the November 2024 consumer engagement workshops.
Strengthening stakeholder engagement through a dedicated Consumer Engagement team.
Expanding public consultation steps to include the annual tender process.
Significantly improved access to medicines and medical technology by:
Engaging with international experts on best practice for considering the societal impacts of funding medicines.
Established the medical devices procurement arrangement with Health NZ.
“The Government’s doing its part. Since this Government took over, we’ve allocated Pharmac its largest ever budget of $7.2 billion over four years,” Mr Seymour says.
This includes a $54 million uplift over 4 years announced in Budget 2026 and a $604 million uplift over 4 years made in June 2024. It also includes the $1.77 billion investment made in Budget 2024 to address previous time limited funding
“Patients are reaping the benefits. With that money, Pharmac has made 135 decisions to fund or widen access to medicines, including decisions on 47 cancer medicines. Over 680,000 patients are expected to benefit in the first year of funding from these medicines,” Mr Seymour says.
“The progress so far has been impressive, but there is more work to be done. Listening to the voices of patients and consumers will continue to be at the heart of Pharmac’s work as it launches the next phase of its long-term improvement programme.”
